ADVERSE EVENT REPORTING OF MARKETING BIOSIMILAR AND BIOLOGICAL MONOCLONAL ANTIBODY CANCER TREATMENTS

被引：0
|
作者：
Xue, X. Xiangzhong [1 ]
Qian, J. [1 ]
机构：
[1] Auburn Univ, Harrison Coll Pharm, Auburn, AL USA
来源：
RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY | 2023年 / 19卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：564 / 564
页数：1
相关论文
共 50 条
  • [1] ADVERSE EVENT REPORTING OF MARKETED BIOSIMILAR AND BIOLOGICAL MONOCLONAL ANTIBODY CANCER TREATMENTS IN THE UNITED STATES
    Xue, X.
    Truong, B.
    Qian, J.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S365 - S366
  • [2] Adverse event reporting of marketed biosimilar and biological monoclonal antibody cancer treatments in the United States
    Xue, Xiangzhong
    Truong, Bang
    Qian, Jingjing
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (08) : 841 - 849
  • [3] Safety of marketed biosimilar monoclonal antibody cancer treatments in the US: a disproportionality analysis using the food and drug administration adverse event reporting system (FAERS) database
    Xue, Xiangzhong
    Qian, Jingjing
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
  • [4] Does the spontaneous adverse event reporting pattern for a monoclonal antibody exhibit the Weber effect?
    Oladipo, A.
    Mendelsohn, A. B.
    Yonren, S.
    [J]. DRUG SAFETY, 2006, 29 (10) : 938 - 938
  • [5] Effects of consumer adverse event reporting for a monoclonal antibody indicated in a paediatric population on risk communication tools
    Oladipo, A.
    Mendelsohn, A. B.
    Roncal, J.
    Yonren, S.
    [J]. DRUG SAFETY, 2006, 29 (10) : 945 - 945
  • [6] Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event reporting system
    Zhao, Jiawei
    Tao, Yong
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [7] Adverse event profile of CGRP monoclonal antibodies: findings from the FDA adverse event reporting database
    Wang, Qi
    Liu, Jingfang
    Sun, Hao
    Dong, Yongfei
    Tan, Weiliang
    Tang, Zaixiang
    Jiang, Yiguo
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024, 23 (01) : 107 - 117
  • [8] Adverse Event Reporting in Cancer Clinical Trial Publications
    Sivendran, Shanthi
    Latif, Asma
    McBride, Russell B.
    Stensland, Kristian D.
    Wisnivesky, Juan
    Haines, Lindsay
    Oh, William K.
    Galsky, Matthew D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (02) : 83 - 89
  • [9] Post-marketing hepatic adverse event reporting in the EU, Japan and USA
    Pasquale, John J.
    Koo, Linda C.
    Vervaet, Piet A. M.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 : S110 - S111
  • [10] Post-marketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA Adverse Event Reporting System (FAERS)
    Zou, Shu-Peng
    Yang, Hai-Yun
    Ouyang, Mengling
    Cheng, Qian
    Shi, Xuan
    Sun, Ming-Hui
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024, 23 (03) : 353 - 362
12345